search

Active clinical trials for "Skin Neoplasms"

Results 281-290 of 522

Preoperative Image-based Education Effect on Postoperative Satisfaction of Patients Undergoing First-time...

Skin CancerSkin Wound

This research study aims to understand whether visual and written education on wound appearance can improve patients' experience and understanding of what their wound will look like following dermatologic surgery.

Not yet recruiting2 enrollment criteria

Study of Topical SOR007 Ointment for Cutaneous Metastases

Cutaneous Metastasis

This study evaluates a topical nanoparticle paclitaxel ointment (SOR007) for the treatment of cutaneous metastases from non-melanoma cancer in adults. Three concentrations of SOR007 will be evaluated in dose-rising cohorts of three. An expanded cohort will treat additional subjects at the maximum tolerated dose.

Completed27 enrollment criteria

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That...

Metastatic MelanomaRecurrent Melanoma5 more

This randomized phase II trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Aldesleukin may stimulate the white blood cells to kill cancer. Ziv-aflibercept may stop the growth of melanoma by blocking blood flow to the tumor. It is not yet known whether aldesleukin is more effective with or without ziv-aflibercept in treating melanoma.

Completed51 enrollment criteria

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Recurrent MelanomaStage III Skin Melanoma1 more

This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Completed38 enrollment criteria

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma...

Recurrent MelanomaStage IIIB Skin Melanoma2 more

This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant melanoma by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.

Completed120 enrollment criteria

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma...

Stage IIA Skin MelanomaStage IIB Skin Melanoma5 more

This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or without toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A-stable oil-in-water emulsion (GLA-SE) in treating patients with stage II-IV melanoma that has been removed by surgery. Vaccines made from MART-1a peptide or antigen may help the body build an effective immune response to kill tumor cells. Giving TLR4 agonist GLA-SE with MART-1 antigen may help increase the immune response to MART-1a antigen.

Completed31 enrollment criteria

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

Mucosal MelanomaRecurrent Melanoma9 more

This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma.

Completed75 enrollment criteria

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin...

Metastatic MelanomaStage IIIB Cutaneous Melanoma AJCC v72 more

This randomized phase II trial studies how well giving pembrolizumab with standard chemotherapy, tumor infiltrating lymphocytes (TIL), and aldesleukin works in treating patients with melanoma that has spread to other areas of the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving an infusion of TIL, or white blood cells, may help stimulate the immune system to help kill more cells. Aldesleukin may also stimulate the white blood cells to kill melanoma cells. Giving pembrolizumab together with standard chemotherapy, TIL, and high- or low-dose aldesleukin may help stop the melanoma from spreading.

Completed53 enrollment criteria

Dietary Prevention of Photodamage in Skin With Grapes

Non-melanoma Skin Cancer

To assess the effect of orally administered grape powder on the sunburn reaction in humans.

Completed11 enrollment criteria

Phase II Trial of Allovectin-7® for Metastatic Melanoma

MelanomaMetastatic Melanoma2 more

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.

Completed5 enrollment criteria
1...282930...53

Need Help? Contact our team!


We'll reach out to this number within 24 hrs